This growth is fueled by the companies popular weight loss and diabetes drugs, Zepbound and Moinjaro. When discussing its second-quarter results in August, company officials said the two drugs accounted for almost 40% of Eli Lilly’s total sales. Those results caused the company’s stock to rise by 10% on Aug. 8, according to CNBC.
Eli Lilly’s current market value is close to $900 million, as of this writing.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
